Indications
Oral contraception. The decision to prescribe Lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).
Composition
- Active substance
- estetrol monohydrate, drospirenone
- International name (INN)
- estetrol;drospirenone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lydisilka
- Active substance
- estetrol monohydrate, drospirenone
- ATC code
- G03
- Therapeutic area